Advisory Committee Renewals; Correction, 53430 [2014-21369]

Download as PDF 53430 Federal Register / Vol. 79, No. 174 / Tuesday, September 9, 2014 / Notices Leroy A. Richardson, Chief, Information Collection Review Office, Office of Scientific Integrity, Office of the Associate Director for Science, Office of the Director, Centers for Disease Control and Prevention. [FR Doc. 2014–21379 Filed 9–8–14; 8:45 am] BILLING CODE 4163–18–P DEPARTMENT OF HEALTH AND HUMAN SERVICES Centers for Disease Control and Prevention Georgia Tuberculosis Outbreak Among Homeless Centers for Disease Control and Prevention (CDC), Department of Health and Human Services (HHS). AGENCY: ACTION: Notice of award. The Centers for Disease Control and Prevention (CDC) located within the United States Department of Health and Human Services (HHS) announces a notice of award to the Georgia Department of Public Health, Tuberculosis (TB) Program. This award will be in the amount of $419,095.00. The purpose of this award is to halt the further spread of a drug-resistant strain of tuberculosis associated with multiple homeless shelters in Fulton County, Georgia. SUMMARY: It is expected the notice of award will begin on or about September 3, 2014. The project period will be for one year. FOR FURTHER INFORMATION CONTACT: Gail Burns-Grant, Division of Tuberculosis Elimination, Field Services and Evaluation Branch, Centers for Disease Control and Prevention, 1600 Clifton Road NE., MS E–10, Atlanta, GA 30333; phone: 404–639–5344; email: GAB2@ cdc.gov. SUPPLEMENTARY INFORMATION: Currently, the state of Georgia is experiencing a public health emergency in Fulton County where there has been extensive transmission of a drug-resistant strain of tuberculosis (TB) associated with multiple homeless shelters in the county. The Georgia Department of Public Health asked CDC to provide emergency funding for the immediate implementation of CDC recommendations provided as a result of a May 2014 outbreak investigation to prevent further transmission of this drug-resistant strain of tuberculosis and to prevent further deaths associated with this outbreak. Project number is CDC–RFA–PS14–1416. DATES: Dated: September 4, 2014. Ron A. Otten, Acting Deputy Associate Director for Science, Centers for Disease Control and Prevention. [FR Doc. 2014–21455 Filed 9–4–14; 4:15 pm] BILLING CODE 4163–18–P DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration [Docket No. FDA–2014–N–0001] Advisory Committee Renewals; Correction AGENCY: Food and Drug Administration, HHS. ACTION: Notice; correction. The Food and Drug Administration (FDA) is correcting a notice entitled ‘‘Advisory Committee Renewals’’ that appeared in the Federal Register of August 25, 2014 (79 FR 50658). The document announced the renewal of certain FDA advisory committees by the Commissioner of Food and Drugs. The table in the document contained several errors. This document corrects those errors. SUMMARY: Lisa Granger, Office of Policy, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 32, rm. 3330, Silver Spring, MD 20993–0002, 301–796–9115. FOR FURTHER INFORMATION CONTACT: In the Federal Register of Monday, August 25, 2014, in FR Doc. 2014–20017, on page 50659 the table is corrected to read: SUPPLEMENTARY INFORMATION: Name of committee Date of expiration Advisory Committee for Pharmaceutical Science and Clinical Pharmacology ....................................................................... Gastrointestinal Drugs Advisory Committee ............................................................................................................................ Bone, Reproductive and Urologic Drugs Advisory Committee (formerly Reproductive Health Drugs Advisory Committee) Arthritis Advisory Committee ................................................................................................................................................... Pharmacy Compounding Advisory Committee ........................................................................................................................ Anesthetic and Analgesic Drugs Advisory Committee ............................................................................................................ Blood Products Advisory Committee ....................................................................................................................................... Pulmonary-Allergy Drugs Advisory Committee ....................................................................................................................... Drug Safety and Risk Management Advisory Committee ....................................................................................................... Science Advisory Board to the National Center for Toxicological Research .......................................................................... Peripheral and Central Nervous System Drugs Advisory Committee .................................................................................... Psychopharmacologic Drugs Advisory Committee ................................................................................................................. Transmissible and Spongiform Encephalopathies Advisory Committee ................................................................................. Science Board to the Food and Drug Administration ............................................................................................................. Allergenic Products Advisory Committee ................................................................................................................................ Dated: September 3, 2014. Jill Hartzler Warner, Associate Commissioner for Special Medical Programs. DEPARTMENT OF HEALTH AND HUMAN SERVICES tkelley on DSK3SPTVN1PROD with NOTICES [Docket No. FDA–2014–N–1049] Exploring the Expansion of Conditional Approval to Appropriate Categories of New Animal Drugs AGENCY: Food and Drug Administration, HHS. VerDate Mar<15>2010 17:39 Sep 08, 2014 Jkt 232001 Notice. The Food and Drug Administration (FDA) is announcing that it is beginning the exploration process described in a stated performance goal in the Animal Drug User Fee Amendments of 2013 (ADUFA III) goals letter. Consistent with the performance goal, the FDA is inviting comments in regard to the Agency exploring the use of statutory changes to expand the use of conditional approval SUMMARY: Food and Drug Administration [FR Doc. 2014–21369 Filed 9–8–14; 8:45 am] BILLING CODE 4164–01–P ACTION: PO 00000 Frm 00025 Fmt 4703 Sfmt 4703 January 22, 2016. March 3, 2016. March 23, 2016. April 5, 2016. April 25, 2016. May 1, 2016. May 13, 2016. May 30, 2016. May 31, 2016. June 2, 2016. June 4, 2016. June 4, 2016. June 9, 2016. June 26, 2016. July 9, 2016. E:\FR\FM\09SEN1.SGM 09SEN1

Agencies

[Federal Register Volume 79, Number 174 (Tuesday, September 9, 2014)]
[Notices]
[Page 53430]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2014-21369]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA-2014-N-0001]


Advisory Committee Renewals; Correction

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice; correction.

-----------------------------------------------------------------------

SUMMARY: The Food and Drug Administration (FDA) is correcting a notice 
entitled ``Advisory Committee Renewals'' that appeared in the Federal 
Register of August 25, 2014 (79 FR 50658). The document announced the 
renewal of certain FDA advisory committees by the Commissioner of Food 
and Drugs. The table in the document contained several errors. This 
document corrects those errors.

FOR FURTHER INFORMATION CONTACT: Lisa Granger, Office of Policy, Food 
and Drug Administration, 10903 New Hampshire Ave., Bldg. 32, rm. 3330, 
Silver Spring, MD 20993-0002, 301-796-9115.

SUPPLEMENTARY INFORMATION: In the Federal Register of Monday, August 
25, 2014, in FR Doc. 2014-20017, on page 50659 the table is corrected 
to read:

------------------------------------------------------------------------
          Name of committee                   Date of expiration
------------------------------------------------------------------------
Advisory Committee for                January 22, 2016.
 Pharmaceutical Science and Clinical
 Pharmacology.
Gastrointestinal Drugs Advisory       March 3, 2016.
 Committee.
Bone, Reproductive and Urologic       March 23, 2016.
 Drugs Advisory Committee (formerly
 Reproductive Health Drugs Advisory
 Committee).
Arthritis Advisory Committee........  April 5, 2016.
Pharmacy Compounding Advisory         April 25, 2016.
 Committee.
Anesthetic and Analgesic Drugs        May 1, 2016.
 Advisory Committee.
Blood Products Advisory Committee...  May 13, 2016.
Pulmonary-Allergy Drugs Advisory      May 30, 2016.
 Committee.
Drug Safety and Risk Management       May 31, 2016.
 Advisory Committee.
Science Advisory Board to the         June 2, 2016.
 National Center for Toxicological
 Research.
Peripheral and Central Nervous        June 4, 2016.
 System Drugs Advisory Committee.
Psychopharmacologic Drugs Advisory    June 4, 2016.
 Committee.
Transmissible and Spongiform          June 9, 2016.
 Encephalopathies Advisory Committee.
Science Board to the Food and Drug    June 26, 2016.
 Administration.
Allergenic Products Advisory          July 9, 2016.
 Committee.
------------------------------------------------------------------------


    Dated: September 3, 2014.
Jill Hartzler Warner,
Associate Commissioner for Special Medical Programs.
[FR Doc. 2014-21369 Filed 9-8-14; 8:45 am]
BILLING CODE 4164-01-P
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.